The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
30501907
DOI
10.1016/j.blre.2018.11.003
PII: S0268-960X(18)30044-4
Knihovny.cz E-resources
- Keywords
- Bone marrow, Multiple myeloma, NF-κB, Proteasome inhibitor, Therapy,
- MeSH
- Enzyme Activation MeSH
- Molecular Targeted Therapy MeSH
- Bone Marrow drug effects metabolism pathology MeSH
- Humans MeSH
- Disease Management MeSH
- Multiple Myeloma diagnosis etiology metabolism therapy MeSH
- NF-kappa B antagonists & inhibitors metabolism MeSH
- Antineoplastic Agents pharmacology therapeutic use MeSH
- Signal Transduction * drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- NF-kappa B MeSH
- Antineoplastic Agents MeSH
Multiple myeloma, which ranks as the second most common hematological malignancy, is known for its great genetic heterogeneity. One pathway, however, stands out in this diverse group. NF-κB pathway is one of the most important pathways in multiple myeloma not only for its role in pathogenesis, but also for its importance in various treatment strategies. Mutations in several major components of the NF-κB pathway and its regulators are present in at least 17% of primary multiple myeloma tumors and 42% of multiple myeloma cell lines. The NF-κB pathway regulates numerous genes, which influence development and pathogenesis of multiple myeloma. This significance of NF-κB for myeloma cells, however, is used against them, as current treatment strategies often use NF-κB as their primary or secondary target.
Babak Myeloma Group Department of Pathological Physiology Masaryk University Brno Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
References provided by Crossref.org
Immunomodulatory Agents for Multiple Myeloma
Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
